Annual EBITDA
-$120.04 M
-$26.78 M-28.72%
December 31, 2022
Summary
- As of February 10, 2025, TCRR annual EBITDA is -$120.04 million, with the most recent change of -$26.78 million (-28.72%) on December 31, 2022.
- During the last 3 years, TCRR annual EBITDA has fallen by -$69.52 million (-137.60%).
Performance
TCRR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
-$36.85 M
-$6.59 M-21.79%
March 31, 2023
Summary
- As of February 10, 2025, TCRR quarterly EBITDA is -$36.85 million, with the most recent change of -$6.59 million (-21.79%) on March 31, 2023.
- Over the past year, TCRR quarterly EBITDA has dropped by -$8.92 million (-31.92%).
Performance
TCRR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$128.39 M
-$8.92 M-7.46%
March 31, 2023
Summary
- As of February 10, 2025, TCRR TTM EBITDA is -$128.39 million, with the most recent change of -$8.92 million (-7.46%) on March 31, 2023.
- Over the past year, TCRR TTM EBITDA has dropped by -$28.28 million (-28.25%).
Performance
TCRR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TCRR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.7% | -31.9% | -28.3% |
| 3 y3 years | -137.6% | -131.5% | -130.1% |
| 5 y5 years | -831.8% | -812.8% | -154.1% |
TCRR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | +28.7% | at low | +59.5% | at low | +37.7% | at low |
| 5 y | 5-year | +137.6% | at low | +177.8% | at low | +154.1% | at low |
| alltime | all time | +1136.2% | at low | +830.3% | at low | +3141.4% | at low |
TCR2 Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$36.85 M(+21.8%) | -$128.39 M(+7.5%) |
| Dec 2022 | -$120.04 M(+28.7%) | -$30.26 M(+0.2%) | -$119.47 M(+6.4%) |
| Sep 2022 | - | -$30.21 M(-2.7%) | -$112.32 M(+4.4%) |
| Jun 2022 | - | -$31.07 M(+11.2%) | -$107.57 M(+7.5%) |
| Mar 2022 | - | -$27.93 M(+20.9%) | -$100.11 M(+7.4%) |
| Dec 2021 | -$93.25 M(+39.0%) | -$23.11 M(-9.3%) | -$93.25 M(+5.7%) |
| Sep 2021 | - | -$25.47 M(+7.9%) | -$88.24 M(+11.0%) |
| Jun 2021 | - | -$23.60 M(+12.0%) | -$79.52 M(+10.0%) |
| Mar 2021 | - | -$21.08 M(+16.5%) | -$72.27 M(+7.7%) |
| Dec 2020 | -$67.11 M | -$18.09 M(+8.0%) | -$67.11 M(+7.7%) |
| Sep 2020 | - | -$16.75 M(+2.5%) | -$62.29 M(+3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | -$16.35 M(+2.7%) | -$60.17 M(+7.8%) |
| Mar 2020 | - | -$15.92 M(+20.0%) | -$55.80 M(+10.5%) |
| Dec 2019 | -$50.52 M(+94.1%) | -$13.27 M(-9.4%) | -$50.52 M(+10.8%) |
| Sep 2019 | - | -$14.64 M(+22.2%) | -$45.58 M(+20.2%) |
| Jun 2019 | - | -$11.97 M(+12.5%) | -$37.91 M(+16.2%) |
| Mar 2019 | - | -$10.64 M(+27.8%) | -$32.64 M(+25.4%) |
| Dec 2018 | -$26.03 M(+102.1%) | -$8.32 M(+19.4%) | -$26.03 M(+20.1%) |
| Sep 2018 | - | -$6.97 M(+4.2%) | -$21.67 M(+47.5%) |
| Jun 2018 | - | -$6.70 M(+65.9%) | -$14.70 M(+83.7%) |
| Mar 2018 | - | -$4.04 M(+1.9%) | -$8.00 M(+101.9%) |
| Dec 2017 | -$12.88 M(+32.7%) | -$3.96 M | -$3.96 M |
| Dec 2016 | -$9.71 M | - | - |
FAQ
- What is TCR2 Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for TCR2 Therapeutics?
- What is TCR2 Therapeutics annual EBITDA year-on-year change?
- What is TCR2 Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for TCR2 Therapeutics?
- What is TCR2 Therapeutics quarterly EBITDA year-on-year change?
- What is TCR2 Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for TCR2 Therapeutics?
- What is TCR2 Therapeutics TTM EBITDA year-on-year change?
What is TCR2 Therapeutics annual EBITDA?
The current annual EBITDA of TCRR is -$120.04 M
What is the all time high annual EBITDA for TCR2 Therapeutics?
TCR2 Therapeutics all-time high annual EBITDA is -$9.71 M
What is TCR2 Therapeutics annual EBITDA year-on-year change?
Over the past year, TCRR annual EBITDA has changed by -$26.78 M (-28.72%)
What is TCR2 Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TCRR is -$36.85 M
What is the all time high quarterly EBITDA for TCR2 Therapeutics?
TCR2 Therapeutics all-time high quarterly EBITDA is -$3.96 M
What is TCR2 Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TCRR quarterly EBITDA has changed by -$8.92 M (-31.92%)
What is TCR2 Therapeutics TTM EBITDA?
The current TTM EBITDA of TCRR is -$128.39 M
What is the all time high TTM EBITDA for TCR2 Therapeutics?
TCR2 Therapeutics all-time high TTM EBITDA is -$3.96 M
What is TCR2 Therapeutics TTM EBITDA year-on-year change?
Over the past year, TCRR TTM EBITDA has changed by -$28.28 M (-28.25%)